Vancomycin-resistant enterococcus infection in the hematopoietic stem cell transplant recipient: an overview of epidemiology, management, and prevention

Esther Benamu; Stanley Deresinski

doi:10.12688/f1000research.11831.1

Vancomycin-resistant enterococcus infection in the hematopoietic stem cell transplant recipient: an overview of epidemiology, management, and prevention

F1000Res. 2018 Jan 2:7:3. doi: 10.12688/f1000research.11831.1. eCollection 2018.

Authors

Esther Benamu¹, Stanley Deresinski²

Affiliations

¹ Division of Infectious Diseases, Department of Medicine, University of Colorado, Aurora, USA.
² Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, USA.

Abstract

Vancomycin-resistant enterococcus (VRE) is now one of the leading causes of nosocomial infections in the United States. Hematopoietic stem cell transplantation (HSCT) recipients are at increased risk of VRE colonization and infection. VRE has emerged as a major cause of bacteremia in this population, raising important clinical questions regarding the role and impact of VRE colonization and infection in HSCT outcomes as well as the optimal means of prevention and treatment. We review here the published literature and scientific advances addressing these thorny issues and provide a rational framework for their approach.

Keywords: Hematopoietic stem cell transplantation; Vancomycin resistant enterococcus; bacteremia.

Publication types

Review

Grants and funding

The author(s) declared that no grants were involved in supporting this work.